| Page 10 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations

Author(s): 
Bodó I, Amine I, Boban A, Bumbea H, Kulagin A, Lukina E, Piekarska A, Zupan IP, Sokol J, Windyga J, Cermak J
Primary Author: 
Bodó I
Journal Title: 
Advances in Therapy
Original Publication Date: 
Jun 2023

Introduction: Hemolysis in

Bone Marrow Disease(s): 

Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy

Author(s): 
Nakamura R, Patel BA, Kim S, Wong FL, Armenian SH, Groarke EM, Kessler DA, Hebert KM, Heim M, Eapen M, Young NS
Primary Author: 
Nakamura R
Journal Title: 
Haematologica
Original Publication Date: 
Jun 2023

Immunosuppressive treatment (IST) and hematopoietic cell transplant (HCT) are standard therapies for severe

Bone Marrow Disease(s): 

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Author(s): 
DeZern AE, Zahurak M, Symons HJ, Cooke KR, Huff CA, Jain T, Swinnen LJ, Imus PH, Wagner-Johnston ND, Ambinder RF, Levis M, Luznik L, Bolaños-Meade J, Fuchs EJ, Jones RJ, Brodsky RA
Primary Author: 
DeZern AE
Journal Title: 
Blood
Original Publication Date: 
Jun 2023

Severe

Bone Marrow Disease(s): 

Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study

Author(s): 
Chen M, Liu Q, Gao Y, Suo X, Ding X, Wang L, Li L, Shao Y, Gao D, Sun W, Tan Y, Wang W, Ye F, Han B
Primary Author: 
Chen M
Journal Title: 
European Journal of Haematology
Original Publication Date: 
Jun 2023

Aims: To compare cyclosporine (CSA) combining eltrombopag (EPAG) with or without antithymocyte globulin (ATG) in

Bone Marrow Disease(s): 

IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria

Author(s): 
Gurnari C, Prata PH, Catto LFB, Durmaz A, Larcher L, Sebert M, Allain V, Kewan T, Pagliuca S, Pinto AL, Inacio MCB, Hernandez L, Dhedin N, Caillat-Zucman S, Clappier E, Sicre de Fontbrune F, Voso MT, Visconte V, Peffault de Latour R, Soulier J, Socié G
Primary Author: 
Gurnari C
Journal Title: 
Blood
Original Publication Date: 
Jun 2023
Bone Marrow Disease(s): 

Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study

Author(s): 
Abel GA, Hebert D, Lee C, Rollison DE, Gillis N, Komrokji RS, Foran JM, Liu JJ, Al Baghdadi T, Deeg HJ, Gore SD, Saber W, Wilson SH, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA
Primary Author: 
Abel GA
Journal Title: 
Blood Advances
Original Publication Date: 
May 2023

Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with

Bone Marrow Disease(s):